|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The involvement of PSD in the pathophysiology of schizophrenia is supported by post mortem studies, preclinical animal models, modulation by antipsychotics, and association of PSD genes with schizophrenia in GWAS.
|
31461641 |
2019 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, gene sets previously implicated in SCZ (i.e., post-synaptic density (PSD) proteins, voltage-gated calcium channels (VGCCs), and fragile X mental retardation protein (FMRP) targets) were found significantly enriched in genes carrying IBD<sub>risk</sub> variants.
|
29411265 |
2018 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities with PSD proteins are linked to various neuropsychiatric diseases including neurodevelopmental disorders such as autism spectrum disorder and schizophrenia.
|
29415158 |
2018 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that rare missense mutations in the candidate PSD genes may increase susceptibility to SZ and/or ASD.
|
27271353 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the genetic relationship of genes expressed in the PSD with schizophrenia, a family-based association analysis of genetic variants in PSD genes such as DLG4, DLG1, PICK1 and MDM2, was performed, using Japanese samples (124 pedigrees, n = 376 subjects).
|
23936182 |
2013 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
As impaired NMDA receptor activity may be the result of a primary defect in the NMDA receptors themselves, or secondary to dysfunction in the protein complexes that mediate their signaling, we measured expression of both NMDA subunits and associated postsynaptic density (PSD) proteins (PSD95, neurofilament-light (NF-L), and SAP102) transcripts in the dorsolateral prefrontal cortex in subjects with schizophrenia, bipolar disorder, major depression, and a comparison group using tissue from the Stanley Foundation Neuropathology Consortium.
|
18033238 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously identified abnormalities of multiple molecules associated with glutamatergic neurotransmission, including changes in NMDA receptor subunit transcripts and binding sites and NMDA receptor-associated post-synaptic density (PSD) protein transcripts in the thalamus of elderly patients with schizophrenia.
|
16762023 |
2006 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia.
|
16702973 |
2006 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia.
|
16702973 |
2006 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression.
|
16023328 |
2005 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of the interaction between smoking and schizophrenia identified several genes in the NMDA-PSD that were differentially affected by smoking in patients.
|
16122832 |
2005 |
|
Autism Spectrum Disorders
|
0.060 |
Biomarker
|
disease |
BEFREE |
This study identifies <i>CAPG</i> and <i>VDAC3</i> as candidate genes and provides additional support for genes encoding PSD proteins in ASD susceptibility.
|
30736458 |
2019 |
|
Autism Spectrum Disorders
|
0.060 |
Biomarker
|
disease |
BEFREE |
Mutations within the <i>Shank3</i> gene, which encodes a key postsynaptic density (PSD) protein at glutamatergic synapses, contribute to the genetic etiology of defined autism spectrum disorders (ASDs), including Phelan-McDermid syndrome (PMS) and intellectual disabilities (ID).
|
30971895 |
2019 |
|
Autism Spectrum Disorders
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The <i>SHANK3</i> gene (and to a lesser degree <i>SHANK2</i>) which encode for the postsynaptic density (PSD) proteins SHANK3/SHANK2 and the <i>CONTACTIN 4</i> gene which encodes for the neuronal glycoprotein CONTACTIN4 (CNTN4) exhibit mutated variants which are associated with ASD.
|
29970989 |
2018 |
|
Autism Spectrum Disorders
|
0.060 |
Biomarker
|
disease |
BEFREE |
Abnormalities with PSD proteins are linked to various neuropsychiatric diseases including neurodevelopmental disorders such as autism spectrum disorder and schizophrenia.
|
29415158 |
2018 |
|
Autism Spectrum Disorders
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that rare missense mutations in the candidate PSD genes may increase susceptibility to SZ and/or ASD.
|
27271353 |
2016 |
|
Autism Spectrum Disorders
|
0.060 |
Biomarker
|
disease |
BEFREE |
Several PSD proteins associated with ASDs are part of a complex centered around ProSAP/Shank proteins and many ProSAP/Shank interaction partners play a role in signaling within dendritic spines.
|
23650259 |
2014 |
|
Glaucoma, Primary Open Angle
|
0.040 |
Biomarker
|
disease |
BEFREE |
There was a significant correlation (p<0.05) between MD, PSD and many DCRs with POAG patients with softer or more compliant corneas more likely to show visual field defects.
|
30923134 |
2020 |
|
Glaucoma, Primary Open Angle
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the POAG group, there was a significant negative correlation between PSD on one hand and P50 amplitude (r=-0.620, P=0.001) and N95 amplitude (r=-0.61, P<0.001) on the other hand.
|
31306362 |
2019 |
|
Glaucoma, Primary Open Angle
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
<b>Abbreviations</b>: POAG = primary open-angle glaucoma; RGC = retinal ganglion cell; OCTA = optical coherence tomography angiography; RNFL = retinal nerve fiber layer; PPG = pre-perimetric primary open-angle glaucoma; EG = early perimetric primary open-angle glaucoma; IOP = intraocular pressure; PSD = pattern standard deviation; MD = mean deviation; GCC = ganglion cell complex; SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial pressure; MOPP = mean ocular perfusion pressure; wiVD = whole image vessel density; ParaVD = parafoveal vessel density; PeriVD = perifoveal vessel density; RPC VD = radial peripapillary capillary vessel density; AUC = area under the receiver operating curve.
|
31587582 |
2019 |
|
Glaucoma, Primary Open Angle
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
POAG subjects with the epsilon2epsilon3 genotype had a worse PSD value (median=2.2) than those with the epsilon3epsilon4 genotype (median=1.77; p=0.01) and POAG subjects with the epsilon3epsilon3 genotype had worse MD and PSD values (median= -7.4 and 3.4, respectively) than those with the epsilon3epsilon4 genotype (median= -4.1 and 1.77, respectively; p=0.034 and 0.028, respectively).
|
19578553 |
2009 |
|
Mental disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Postsynaptic density (PSD) proteins have been implicated in the pathophysiology of neurodevelopmental and psychiatric disorders.
|
31616000 |
2019 |
|
Speech Delay
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: CAS: Childhood Apraxia of Speech; CD: Childhood Dysarthria; DS: Down syndrome; II: Intelligibility Index; No MSD: No Motor Speech Disorder; OII: Ordinal Intelligibility Index; PSD: Persistent Speech Delay; SDCS: Speech Disorders Classification System; SMD: Speech Motor Delay.
|
31221010 |
2019 |
|
Speech Delay
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> CAS: Childhood Apraxia of Speech; CD: Childhood Dysarthria; DS: Down syndrome; NSA: Normal(ized) Speech Acquisition; PSD: Persistent Speech Delay; PSE: Persistent Speech Errors; SD: Speech Delay; SDCS: Speech Disorders Classification System; SE: Speech Errors; SMD: Speech Motor Delay.
|
31221009 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Finally, both in vivo distribution and in vivo antitumor showed the R<sub>7</sub>/PSD-Fol NPs displayed the better distribution at tumor site and the stronger suppression of tumor growth in the tumor bearing nude mice compared with control group.
|
28291364 |
2017 |